SPRINGFIELD, Ill. — The Illinois Department of Public Health will resume the use of Johnson & Johnson’s COVID-19 vaccine after U.S. health officials lifted the pause on it Friday afternoon.
Scientific advisers decided its benefits outweigh a rare risk of blood clot after 15 vaccine recipients developed them. Nearly 8 million people were given the Johnson & Johnson shot in the U.S.
Providers in Illinois who previously received doses of the vaccine will be able to immediately begin administering it. Allocations of the Johnson & Johnson vaccine by the federal government will resume next week.
Approximately 760,000 doses were allocated to Illinois before the pause, of which approximately 290,000 were administered.
“The pause was proof that the extensive safety monitoring system is working and was able to detect a very small number of adverse events. The FDA has concluded that the known and potential benefits of the J&J vaccine outweigh its known and potential risks,” IDPH said in a release.
The Chicago Department of Public Health will follow Illinois’ lead and also distribute the Johnson & Johnson vaccine.
On Friday, Illinois reported 3,369 new cases of COVID-19 with 22 additional deaths.